|Bid||2.61 x 1000|
|Ask||2.80 x 2000|
|Day's range||2.62 - 2.69|
|52-week range||2.51 - 5.74|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jan 2018 - 5 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.03|
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Despite some bright points, a revenue miss and contracting margins in the company's third-quarter report are taking a toll.
The genetic-sequencing company's higher system sales aren't enough to offset the loss of contract revenue from Roche.
Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.
On a per-share basis, the Menlo Park, California-based company said it had a loss of 19 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.